盐酸左卡巴斯汀(Levocabastine Hydrochloride) - 药物靶点：H1 receptor_在研适应症：季节性过敏性鼻炎，变应性结膜炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Histimet、Levocabastine、Levocabastine Hydrochloride Nasal Spray

+ [13]

靶点

H1 receptor

作用方式

拮抗剂

作用机制

H1 receptor拮抗剂(组胺H1受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Johnson & Johnson Consumer NVJanssen Pharmaceutical KK

Santen Pharmaceutical Co., Ltd.

非在研机构

GSK Plc

Novartis Pharmaceuticals Corp.

最高研发阶段批准上市

首次获批日期

美国 (1993-11-10),

变应性结膜炎常年性变应性鼻炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C26H29FN2O2

InChIKeyZCGOMHNNNFPNMX-KYTRFIICSA-N

CAS号79516-68-0

查看全部结构式(2)

关联

7

项与盐酸左卡巴斯汀相关的临床试验

NCT04002349

/ Unknown statusN/A

Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

开始日期2019-07-01

申办/合作机构

北京同仁医院管理有限公司

[+1]

KCT0004672

/ CompletedN/AIIT

Double blind, randomized controlled study to evaluate the efficacy and safety of extract of leaves of Dendropanax morbiferous H. Lev on the glucose metabolism

开始日期2018-07-23

申办/合作机构-

JPRN-UMIN000017531

/ RecruitingN/AIIT

Evaluation of the effect of the antiepiletic levetiracetum on seizure control and expression of MGMT in patients with gliomas (Phase II clinical trial) - LEV for Glioma

开始日期2014-10-06

申办/合作机构-

100 项与盐酸左卡巴斯汀相关的临床结果

登录后查看更多信息

100 项与盐酸左卡巴斯汀相关的转化医学

登录后查看更多信息

100 项与盐酸左卡巴斯汀相关的专利（医药）

登录后查看更多信息

2,026

项与盐酸左卡巴斯汀相关的文献（医药）

2025-05-01·Journal of Environmental Sciences

Ingenious construction of a magnetic-recyclable photo-Fenton catalyst ZnFe2O4@MIL-88A(Fe) and its adsorption-degradation activity toward levofloxacin

Article

作者: Ma, Na ; Dai, Wei ; Cao, Dan ; Mi, Xichen ; Chen, Yitong ; Wang, Tingwei

Monotonic pore size and particles inseparability of metal-organic frameworks (MOFs) caused serious effects on its light absorption ability and charge separation, restricting its application for antibiotic such as levofloxacin (LEV) degradation in water. In this study, a magnetically detachable nano-photocatalyst (ZnFe₂O₄@MIL-88A(Fe)) was synthesized using a simple two-step hydrothermal technique. The morphology and microstructure analyses showed that n-type ZnFe₂O₄ catalyst particles were efficiently assembled onto the surface of MIL-88A(Fe) crystal. Photocatalytic activity studies indicated that the ZnFe₂O₄@MIL-88A(Fe) plus H₂O₂ exhibiting a significantly boosted photo-Fenton activity toward LEV at visible light irradiation, compared to the pure ZnFe₂O₄ and MIL-88A(Fe), the degradation efficiency accordingly reached up to nearly 82% and 25% within 60 min. This excellent photocatalytic performance was ascribed to the synergistic effects of the heterogeneous structure of ZnFe₂O₄ and MIL-88A(Fe), whereby the efficient separation of charge carriers in the catalytic system is mutually reinforced with the efficient reduction of Fe³⁺ and Fe²⁺. Meanwhile, the degradation mechanism and intermediates of LEV during the photo-Fenton reaction process were also studied in depth through free radical burst, electron paramagnetic resonance, and mass spectrometry analyses, etc. Additionally, the ZnFe₂O₄@MIL-88A(Fe) composite catalyst displayed significant stability and ease of separation, indicating potential for the photo-oxidative degradation of organic pollutants.

2025-05-01·Journal of Hazardous Materials

Prediction and mechanism of combined toxicity of surfactants and antibiotics in aquatic environment based on in silico method

Article

作者: Ni, Hong-Gang ; Zheng, Zi-Yi ; Wei, Xing-Peng ; Yang, Yu-Ting

The coexistence of surfactants and antibiotics in aquatic environments can potentially trigger combined toxic effects on aquatic organisms. Unfortunately, the effects of these joint toxins and the corresponding mechanism remain unclear. In this study, we performed individual and combined toxicity experiments involving surfactants and antibiotics. Six quantitative structure-activity relationship (QSAR) models and two traditional mixture models were developed. Moreover, the toxic mechanisms were explored with molecular dynamics (MD) simulations and density functional theory (DFT) calculations. The results shown that synergistic toxicity effects were observed in the binary mixture of levofloxacin (LEV) and octylphenol ethoxylate (Triton X-100). In addition, the best QSAR model (RF-PLS), which included four mixture descriptors (RDF155i^#3, MATS3e^#2, ETA_BetaP_ns^#6, MLFER_E^#6) exhibited excellent performance (R² = 0.921, R²_adj = 0.875, Q²_LOO = 0.820, Q²_ext = 0.889, and CCC = 0.954). Further analysis revealed that the electrostatic potential of different target chemicals and their binding ability with enzymes affected the activity of AChE of Daphnia magna, resulting in different toxicity. Specifically, in the AChE + Triton X-100 + LEV system, the second pollutant enhances the ability of the overall system to bind pollutants, which exhibit a synergistic effect during the binding process.

2025-05-01·Food Chemistry

Flavour enhancement of dry fermented sausages by nitrite-degrading Levilactobacillus brevis CHOL1: Combining flavouromics and lipidomics to elucidate the mechanism of aroma formation

Article

作者: Zhao, Ning ; Zhang, Sufang ; Dai, Yiwei ; Yue, Ying ; Lin, Xinping ; Ji, Chaofan ; Chen, Yingxi ; Yin, Shufeng ; Zhu, Beiwei

Levilactobacillus brevis CHOL1, exhibiting a nitrite degradation rate of 99.03 %, was added to dry fermented sausages to evaluate its effects on product quality, sensory and aroma properties. Lipidomics analysis was performed to explore the mechanism of aroma formation after inoculation. Results showed that Lev. brevis CHOL1 reduced the sausages' pH, water activity, and nitrite residues. Inoculation also imparted desirable texture and sensory characteristics to the sausages. Furthermore, significant increases in alcohol, acid and ester contents were observed, which enhanced the aroma of the sausages. Correlation analysis revealed that Lev. brevis CHOL1 promoted the hydrolysis of PC 36:2 and PC 35:2, thereby facilitating the production of key aroma compounds such as heptanol, hexanol and octanol. These components improved the aroma profile of the sausages. These findings indicate that Lev. brevis CHOL1 inoculation is a promising method to reduce the content of nitrite residues and improve the flavour of dry fermented sausages.

100 项与盐酸左卡巴斯汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01717	盐酸左卡巴斯汀	R01AC02 S01GX02	DB01106

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
季节性过敏性鼻炎	中国	Johnson & Johnson Consumer NV	2018-07-24
变应性结膜炎	日本	Santen Pharmaceutical Co., Ltd.	2000-09-22
变应性结膜炎	日本	Janssen Pharmaceutical KK	2000-09-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
季节性常年性变应性鼻炎	药物发现	加拿大	GSK Plc	2013-10-01
季节性常年性变应性鼻炎	药物发现	奥地利	GSK Plc	2013-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01949051 (CTgov)	临床2期	季节性常年性变应性鼻炎	78	placebo (Placebo)	壓膚觸觸蓋顧製糧衊選(簾選顧艱鏇網窪鑰鏇蓋) = 構網夢獵願齋夢淵襯築積醖餘積鬱積齋夢憲壓 (築鹹簾鑰醖衊襯簾願壓, 糧築窪顧衊鏇淵選襯鹹 ~ 餘願廠廠艱淵鏇獵鏇簾) 更多	-	2014-09-25
				Levocabastine (Levocabastine 200µg OD)	壓膚觸觸蓋顧製糧衊選(簾選顧艱鏇網窪鑰鏇蓋) = 淵遞鬱顧憲繭範遞鏇獵積醖餘積鬱積齋夢憲壓 (築鹹簾鑰醖衊襯簾願壓, 鑰積鹽襯願醖艱鹹衊願 ~ 構鏇淵壓獵遞壓鹽衊鑰) 更多
ARVO2007	N/A	结膜疾病 ICAM-1 \| VLA-4 \| VCAM-1	-	Levocabastine	鬱製簾繭簾鏇壓糧顧築(艱衊窪鹹遞窪廠蓋鏇蓋) = 構選蓋蓋遞製製選築選夢積簾廠醖廠構鑰艱鏇 (簾觸壓窪簾廠鹽醖夢襯 )	-	2007-05-01
ARVO2003	N/A	季节性过敏性结膜炎	-	Epinastine HCl 0.05%	(窪廠積夢醖襯鑰積鹹鏇) = 願衊選衊網繭觸壓顧壓憲憲觸廠網網網遞願獵 (鬱觸築鑰獵廠遞艱衊艱 )	积极	2003-05-01
				Levocabastine 0.05%	(窪廠積夢醖襯鑰積鹹鏇) = 鑰艱簾觸鹹觸齋壓積夢憲憲觸廠網網網遞願獵 (鬱觸築鑰獵廠遞艱衊艱 )